CATB
Catabasis Pharmaceuticals, Inc. [CATB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CATB Stock Summary
In the News
Catabasis Renames As Astria Therapeutics With New Disease Focus
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy.
Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect
Catabasis Pharmaceuticals Inc (NASDAQ: CATB) deployed a reverse stock split of its shares of common stock at a ratio of 1-for-6. These are the details.
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
CATB Stock Price Increases Over 40% Pre-Market: Why It Happened
The stock price of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) increased by over 40% pre-market. This is why it happened.
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
With the trading day halfway over, the broad markets were making yet another strong push.
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today
Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today appeared first on InvestorPlace.
Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know
Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know appeared first on InvestorPlace.
CATB Financial details
Company Profile
- Volume Average 528.92K
- Market Capitalization 234.86M
- Employee 20
- CEO Dr. Jill Milne
- Headquarters Boston,MASSACHUSETTS,US
- IPO Date 2015-06-25
-
Website
http://www.catabasis.com 
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
